Novartis and Par Antitrust Litigation
DiCello Levitt Secures $30M From Novartis To Settle Class Action Over Exforge Antitrust Claims. In October 2023, DiCello Levitt obtained final approval from the U.S. District Court for the Southern District of New York for a $30 million settlement with drugmaker Novartis to resolve a complex antitrust class action involving the hypertension medication Exforge. In … Continued